Notwithstanding promising clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from PBMs. These organizations are frequently creating limitations to coverage, such as steep price restrictions and prior authorization that hinder patient opportunity. … Read More